405517-54-6

Basic information

• Product Name: 2-IODO-4-(TRIFLUOROMETHOXY)PHENOL
• Synonyms: 2-IODO-4-(TRIFLUOROMETHOXY)PHENOL
• CAS NO: 405517-54-6
• Molecular Formula: C₇H₄F₃IO₂
• Molecular Weight: 304.01
• Mol File: 405517-54-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-IODO-4-(TRIFLUOROMETHOXY)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-IODO-4-(TRIFLUOROMETHOXY)PHENOL(405517-54-6)
• EPA Substance Registry System: 2-IODO-4-(TRIFLUOROMETHOXY)PHENOL(405517-54-6)

Safety Data

• Hazardous Substances Data: 405517-54-6(Hazardous Substances Data)

Upstream product

• 828-27-3 4-Trifluoromethoxyphenol 
• 124-40-3 dimethyl amine 

Downstream Products

• 405517-55-7 1-(2-chloroethoxy)-2-iodo-4-trifluoromethoxybenzene 
• 467467-30-7 2-(2-iodo-4-trifluoromethoxyphenyloxy)-1-(p-toluenesulphonyloxy)propane 
• 1354818-94-2 5-chloro-2-fluoro-4-[2-pyridazin-4-yl-4-(trifluoromethoxy)phenoxy]-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1235407-49-4 2-pyridazin-4-yl-4-(trifluoromethoxy)phenol 

Relevant articles and documents

Novel Cyclopropabenzofuranyl Pyridopyrazinediones

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, R10, R11, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Stereocontrolled preparation of a nonpeptidal (-)-spirobicyclic NK-1 receptor antagonist

The synthesis of a spirobicyclic NK-1 receptor (Substance-P) antagonist 1 antipode is described. Retrosynthetic analysis reveals an allylic halide A bearing the cyclopropoxy-substituted aryl group and a 2-phenyl-3-piperidone B. The stereochemistry in the spirobicyclic system bearing three chiral centers is initially set via a highly diastereoselective zinc-mediated coupling of the allylic bromide 23 to the optically active ketopiperidine 3. The remaining benzylic asymmetric center is set by a diastereoselective hydroboration followed by cyclization to the spirobicyclic system.